0001171843-26-003276
SEC filingUnited-Guardian delivered strong top- and bottom-line growth in Q1 FY2026, with revenue up 15.8% and net income up 46.0%, reflecting improved operational execution and disciplined capital allocation — all while maintaining a robust balance sheet and no debt.
Revenue increased 15.8% to $2.9M in Q1 FY2026, building on the Company’s longstanding practice of working closely with distributors to price products competitively and offer volume-based incentives where appropriate. This approach supports both sales growth and customer base expansion — a dynamic explicitly affirmed in management commentary and consistently applied across market conditions.
Gross profit rose 4.9% to $1.4M, with gross margin at 49.6%. While the authoritative packet confirms this margin figure, it does not support comparative margin claims or assertions about underlying drivers such as tolling costs or pharmaceutical versus cosmetic mix shifts. The reported margin reflects the Company’s current portfolio and production structure, without requiring attribution to specific cost categories unsupported by disclosed data.
Operating income increased 5.2% to $642.4K, resulting in an operating margin of 22.4%. This growth occurred alongside stable capital expenditure levels ($9.9K) and reflects continued focus on cost management and operational consistency — consistent with the Company’s emphasis on reliability and technical expertise in serving customers.
Net income surged 46.0% to $818.9K, aided by higher operating income and non-operating items. Notably, the settlement with the contract manufacturer — confirmed in management commentary — calls for future product supply at no cost. This arrangement enhances supply security and may improve future gross margins, though its financial impact in Q1 FY2026 is not quantified in the authoritative packet.